Can you provide the average price target for BIODESIX INC stock?
11 analysts have analysed BDSX and the average price target is 30.6 USD. This implies a price increase of 210.03% is expected in the next year compared to the current price of 9.87.
BIODESIX INC (BDSX) Forecast, Price Target & Analyst Ratings
NASDAQ:BDSX • US09075X2071
Current stock price
9.87 USD
-0.08 (-0.8%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIODESIX INC (BDSX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.12
- Revenue Estimate
- 23.644M
Price Target Details & History
Consensus Price Target and Range
Mean target
$30.60
Upside
+ 210.03%
From current price of $9.87 to mean target of $30.60, Based on 11 analyst forecasts
Low
$20.20
Median
$30.60
High
$42.00
Price Target Revisions
1 Month
-7.69%
3 Months
-7.69%
Price Target Summary
11 Wall Street analysts provided a forecast for the next 12 months for BDSX. The average price target is 30.6 USD. This implies a price increase of 210.03% is expected in the next year compared to the current price of 9.87.
The average price target has been revised downward by 7.69% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
83.64%
BDSX was analyzed by 11 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about BDSX.
In the previous month the buy percentage consensus was at a similar level.
BDSX was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-27 | William Blair | Upgrade | Market Perform -> Outperform |
| 2026-02-17 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-09-19 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-05-21 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-05-14 | Lake Street | Maintains | Buy -> Buy |
| 2025-05-14 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-05-14 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-05-14 | Craig-Hallum | Maintains | Buy -> Buy |
| 2025-04-29 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-09-16 | ScotiaBank | Initiate | Sector Outperform |
| 2024-07-26 | Craig-Hallum | Initiate | Buy |
| 2024-05-13 | TD Cowen | Initiate | Buy |
| 2024-05-03 | Lake Street | Initiate | Buy |
| 2024-03-04 | Canaccord Genuity | Reiterate | Buy -> Buy |
| 2023-12-07 | Canaccord Genuity | Reiterate | Buy -> Buy |
| 2022-05-12 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-04-20 | Cowen & Co. | Initiate | Outperform |
| 2021-11-17 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-05-12 | Morgan Stanley | Maintains | Overweight |
| 2021-03-18 | Morgan Stanley | Maintains | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.12
- Revenue Estimate
- 23.644M
- Revenue Q2Q
- 31.66%
- EPS Q2Q
- 30.13%
- Number of Analysts
- 7
Next Earnings Revisions
Revenue (1 Month)
0.70%
Revenue (3 Months)
-2.21%
EPS (1 Month)
-1.86%
EPS (3 Months)
-3.89%
Next Earnings Summary
BDSX is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -1.12 USD and the consensus revenue estimate is 23.64M USD.
The next earnings revenue estimate has been revised downward by 2.21% in the past 3 months.
Full Analyst Estimates 2026 - 2028
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 49.087M 28.47% | 71.323M 45.30% | 88.499M 24.08% | 110.85M 25.26% | 132.08M 19.15% | 155.14M 17.46% | |
| EBITDA YoY % growth | -37.97M 19.06% | -28.487M 24.97% | -22.096M 22.43% | -8.024M 63.69% | 1.462M 118.22% | 14.178M 869.77% | |
| EBIT YoY % growth | -41.298M 18.24% | -34.26M 17.04% | -27.766M 18.96% | -21.081M 24.07% | -11.985M 43.15% | -9.027M 24.68% | |
| Operating Margin | -84.13% | -48.03% | -31.37% | -19.02% | -9.07% | -5.82% | |
| EPS YoY % growth | -13.00 59.12% | -7.00 46.15% | -4.85 30.71% | -3.14 35.35% | -1.98 36.69% | -1.36 31.65% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.12 30.13% | -0.86 45.94% | -0.75 35.11% | -0.42 14.24% | -0.90 19.10% | -0.64 25.71% | -0.52 30.89% | -0.19 54.69% |
| Revenue Q2Q % growth | 23.644M 31.66% | 26.704M 33.40% | 28.05M 28.86% | 32.477M 29.14% | 29.24M 23.67% | 31.892M 19.43% | 33.422M 19.15% | 37.706M 16.10% |
| EBITDA Q2Q % growth | -5.168M 32.21% | -3.23M 52.62% | -1.972M 28.58% | 2.21M -40.33% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.88M 13.06% | -6.197M 36.07% | -5.177M 26.51% | -1.734M 11.80% | -6.222M 21.04% | -4.284M 30.86% | -3.57M 31.03% | -2.346M -35.29% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
19.82%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
21.25%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
34.88%
EBIT Next 5 Year
N/A
BIODESIX INC / BDSX Forecast FAQ
When does BIODESIX INC (BDSX) report earnings?
BIODESIX INC (BDSX) will report earnings on 2026-05-11.
What are the consensus estimates for BDSX stock next earnings?
The consensus EPS estimate for the next earnings of BIODESIX INC (BDSX) is -1.12 USD and the consensus revenue estimate is 23.64M USD.
What is the number of analysts for BDSX stock?
The number of analysts covering BIODESIX INC (BDSX) is 11.